drugset / Trial / NCT00276692

Irinotecan in Treating Patients With Newly Diagnosed Ewing's Sarcoma

NCT00276692 ↗

Phase 2 Completed 35 enrolled Children's Cancer and Leukaemia Group
Open-labelTreatment

Summary

RATIONALE: Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well irinotecan works in treating patients with newly diagnosed Ewing's sarcoma.

Timeline

Start
2003-08
Primary completion
2008-09
Completion
2009-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule — Intravenous

Indications